noscript

News and Announcements

Van Leeuwenhoeck Institute initiates Research Coverage with OncoSil

  • Published October 02, 2015 4:41PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

1st October 2015, ASX Announcement

OncoSil Medical Limited (OncoSil Medical, the Company) is pleased to announce that international life sciences research group, Van Leeuwenhoeck Institute, has initiated analyst research coverage on the Company.

The Van Leeuwenhoeck Institute research report is available via the OncoSil Medical company website;

www.oncosil.com.au

OncoSil Medical is focused on the commercialisation of its lead product candidate, the OncoSil localised radiation treatment for cancer. It is concurrently seeking a Conformité Européenne (CE) Mark for OncoSil for pancreatic and primary liver cancer (HCC), which would facilitate commercialisation in the European Union and other major markets (including Australia, Canada and Singapore), and US approval via the US FDA.

To read the full announcement, please click here.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now